Nantahala Capital Management LLC Makes New $8.97 Million Investment in Fractyl Health, Inc. $GUTS

Nantahala Capital Management LLC acquired a new stake in Fractyl Health, Inc. (NASDAQ:GUTS) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 11,289,096 shares of the company’s stock, valued at approximately $8,968,058. Nantahala Capital Management LLC owned 0.07% of Fractyl Health as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Pale Fire Capital SE boosted its position in Fractyl Health by 84.5% in the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after buying an additional 2,711,103 shares during the last quarter. Atom Investors LP acquired a new stake in Fractyl Health during the 4th quarter valued at approximately $4,143,000. General Catalyst Group Management LLC acquired a new stake in Fractyl Health during the 2nd quarter valued at approximately $3,880,000. 683 Capital Management LLC lifted its stake in Fractyl Health by 30.1% during the 4th quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock valued at $13,305,000 after acquiring an additional 1,397,620 shares during the period. Finally, Centiva Capital LP purchased a new stake in shares of Fractyl Health in the 3rd quarter valued at $78,000.

Wall Street Analyst Weigh In

GUTS has been the topic of a number of research reports. Wall Street Zen lowered shares of Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings upgraded shares of Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Craig Hallum started coverage on shares of Fractyl Health in a report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research report on Thursday, June 4th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Fractyl Health presently has an average rating of “Hold” and a consensus target price of $5.50.

Insider Activity

In other news, Director Ian Sheffield acquired 35,000 shares of the stock in a transaction that occurred on Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, for a total transaction of $25,550.00. Following the acquisition, the director owned 35,000 shares in the company, valued at approximately $25,550. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William Bradley bought 68,493 shares of the company’s stock in a transaction dated Wednesday, June 10th. The shares were acquired at an average cost of $0.73 per share, with a total value of $49,999.89. Following the acquisition, the director directly owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. This represents a 424.66% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have purchased 171,493 shares of company stock valued at $127,150. Insiders own 8.52% of the company’s stock.

Fractyl Health Price Performance

Shares of NASDAQ GUTS opened at $0.66 on Friday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15. The firm has a fifty day moving average of $0.75 and a 200 day moving average of $0.66. The firm has a market cap of $104.90 million, a PE ratio of -0.75 and a beta of 2.32. Fractyl Health, Inc. has a one year low of $0.38 and a one year high of $2.44.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. As a group, research analysts predict that Fractyl Health, Inc. will post -0.53 EPS for the current fiscal year.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.